epoetin alfa

Phase 2/3Completed

0 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blood Transfusion

Conditions

Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery, Cardiovascular Surgical Procedures, Mammaplasty

Trial Timeline

— → Nov 1, 1991

NCT ID

NCT00270023

About epoetin alfa

epoetin alfa is a phase 2/3 stage product being developed by Johnson & Johnson for Blood Transfusion. The current trial status is completed. This product is registered under clinical trial identifier NCT00270023. Target conditions include Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures.

What happened to similar drugs?

7 of 17 similar drugs in Blood Transfusion were approved

Approved (7) Terminated (6) Active (7)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

🔄Beriplex® P/N (Kcentra) + Fresh frozen plasmaCSLPhase 3

🔄Fibrinogen Concentrate (Human) (FCH) + PlaceboCSLPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00270010	Phase 2	Completed	—	Aug 1, 1989	Anemia
NCT00266617	Phase 2	Completed	—	Jun 1, 1990	Anemia
NCT00002022	Pre-clinical	Completed	—	—	HIV Infections
NCT00269984	Phase 2	Completed	—	Jun 1, 1990	Anemia
NCT00269945	Phase 2	Completed	—	Jan 1, 1989	Anemia
NCT00270114	Phase 2/3	Completed	—	Mar 1, 1991	Anemia
NCT00446602	Phase 2	Withdrawn	—	Aug 1, 2009	Myelodysplastic Syndromes
NCT00270179	Phase 3	Completed	—	May 1, 1988	Anemia
NCT00269997	Phase 2	Completed	—	Jul 1, 1990	Anemia
NCT00270023	Phase 2/3	Completed	—	Nov 1, 1991	Blood Transfusion
NCT00270270	Phase 2	Completed	—	Jul 1, 1989	Acquired Immunodeficiency Syndrome
NCT00337935	Phase 2	Completed	Jul 1, 2006	Jul 1, 2009	Renal Failure , Chronic
NCT00306267	Phase 2	Terminated	Mar 1, 2006	May 1, 2007	Anemia
NCT00641589	Phase 1	Completed	Jan 1, 2006	Nov 1, 2006	Chronic Kidney Disease
NCT00246298	Phase 2	Terminated	Oct 1, 2005	Sep 1, 2006	Anemia
NCT00212875	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Chronic Kidney Disease
NCT00236405	Phase 2	Terminated	Mar 1, 2005	Oct 1, 2005	Anemia
NCT00240734	Phase 2	Terminated	Mar 1, 2005	Sep 1, 2005	Anemia
NCT00210587	Phase 3	Completed	Feb 1, 2005	Dec 1, 2005	Anemia
NCT00236678	Phase 2	Terminated	Jul 1, 2004	Jan 1, 2006	Anemia

Competing Products

20 competing products in Blood Transfusion

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35
Darbepoetin alfa	Amgen	Phase 1/2	32